Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756134 | 0.96 | NPC1 (0.59) | HTR2BNPC1RAB9AKDM4EMAPT | |
| SCHEMBL724921 | 0.95 | NPC1 (0.62) | HTR2BNPC1RAB9AKDM4EMAPT | |
| SCHEMBL6757201 | 0.95 | NPC1 (0.62) | HTR2BNPC1RAB9AKDM4EMAPT | |
| SCHEMBL2276872 | 0.92 | ALDH1A1 (0.59) | HTR2BNPC1RAB9AKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL31596380 | 0.91 | MAPT (0.57) | HTR2BNPC1RAB9AKDM4EMAPT | |
| SCHEMBL3213543 | 0.86 | KDM4E (0.46) | HTR2BNPC1RAB9AKDM4EMAPT | |
| SCHEMBL6756130 | 0.86 | NPC1 (0.47) | HTR2BNPC1RAB9AKDM4ENPY5R | |
| SCHEMBL14192852 | 0.86 | KDM4E (0.46) | HTR2BNPC1RAB9AKDM4EMAPT | |
| SCHEMBL4429138 | 0.86 | KDM4E (0.46) | HTR2BNPC1RAB9AKDM4EMAPT | |
| SCHEMBL2491336 | 0.86 | HTR2B (0.52) | HTR2BMAPTNPY5RPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116162926-A | Copper surface antioxidant composition and preparation method thereof | 深圳市正天伟科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| EP-2919781-B1 | CYCLOBUTYL BENZIMIDAZOLES AS PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2740730-B1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-9284302-B2 | Cyclobutyl benzimidazoles as PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284302-B2 | Cyclobutyl benzimidazoles as PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284302-B2 | Cyclobutyl benzimidazoles as PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150307479-A1 | CYCLOBUTYL BENZIMIDAZOLES AS PDE 10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307479-A1 | CYCLOBUTYL BENZIMIDAZOLES AS PDE 10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2919781-A1 | CYCLOBUTYL BENZIMIDAZOLES AS PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2919781-A1 | CYCLOBUTYL BENZIMIDAZOLES AS PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007117778-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-07-08 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| US-6712262-B2 | BENZIMIDAZOLE AND IODINE COMPOUNDS | TAMURAKAKEN CORPORATION (JP) | 2004-03-30 | — | — | US | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307479-A1 | CYCLOBUTYL BENZIMIDAZOLES AS PDE 10 INHIBITORS | PDE10A, PDE12, PDE4A | HTR2B 47/4885NPC1 4097/4885RAB9A 639/4885 |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | HTR2B 3530/4885NPC1 2672/4885RAB9A 1216/4885 |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | NOS2, NOS1, NQO2 | HTR2B 3435/4885NPC1 1303/4885RAB9A 1758/4885 |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | HTR2B 3530/4885NPC1 2672/4885RAB9A 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.